The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions. © 2013 Schiffner et al.; licensee BioMed Central Ltd.
CITATION STYLE
Schiffner, T., Sattentau, Q. J., & Dorrell, L. (2013, July 17). Development of prophylactic vaccines against HIV-1. Retrovirology. https://doi.org/10.1186/1742-4690-10-72
Mendeley helps you to discover research relevant for your work.